Recombinant Human-Soluble Thrombomodulin Contributes to Reduced Mortality in Sepsis Patients With Severe Respiratory Failure: A Retrospective Observational Study Using a Multicenter Dataset

Overview

Journal Shock

Date 2018 Mar 30

PMID 29596106

Citations 10

Authors

Shodai Yoshihiro

Masaaki Sakuraya

Mineji Hayakawa

Kota Ono

Akira Hirata

Akihiro Takaba

Natsuki Kawamura

Toru Tsutsui

Kenichi Yoshida

Yoshihiro Hashimoto

Affiliations

Soon will be listed here.

Abstract

Background: Recombinant human-soluble thrombomodulin (rhTM) is a novel class therapeutic agent for managing disseminated intravascular coagulation. The progression of severe respiratory failure may be related to intra-alveolar coagulation/fibrinolytic disorders. We aimed to determine the efficacy of rhTM in treating sepsis patients with severe respiratory failure.

Methods: We performed a retrospective observational study using an existing dataset collected from 42 intensive care units (ICUs) in Japan. Of 3,195 patients with severe sepsis or septic shock from the dataset, we selected sepsis patients with severe respiratory failure, and compared patient outcomes based on the administration of rhTM (rhTM group and no rhTM group). Propensity score analysis was performed between the two groups. Outcomes of interest were ICU mortality, hospital mortality, and ventilator-free days (VFDs).

Results: In this study, 1,180 patients (rhTM, n = 356; no rhTM, n = 824) were analyzed. After adjusting for baseline imbalances with propensity score matching, the survival-time analysis revealed a significant difference between the two groups (hazard ratio, 0.654; 95% confidence interval, 0.439-0.974, P = 0.03). ICU mortality was lower in the rhTM group (rhTM: 22.1% [33/149] vs. no rhTM: 36.2% [54/149], P = 0.01). Hospital mortality was also lower in the rhTM group (35.6% [53/149] vs. 49.7% [74/149], P = 0.02). VFDs trended to be higher in the rhTM group than the no rhTM group (12.8 ± 10.1 days vs. 10.6 ± 10.6 days, P = 0.09).

Conclusions: Administration of rhTM was positively correlated with a reduction in mortality in sepsis patients with severe respiratory failure.

Citing Articles

Endothelial dysfunction and immunothrombosis in sepsis.

Maneta E, Aivalioti E, Tual-Chalot S, Emini Veseli B, Gatsiou A, Stamatelopoulos K Front Immunol. 2023; 14:1144229.

PMID: 37081895 PMC: 10110956. DOI: 10.3389/fimmu.2023.1144229.

The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.

Wulandari S, Hartono , Wibawa T Immunology. 2022; 169(2):117-131.

PMID: 36571562 PMC: 9880760. DOI: 10.1111/imm.13623.

Combination therapy of Ulinastatin with Thrombomodulin alleviates endotoxin (LPS) - induced liver and kidney injury via inhibiting apoptosis, oxidative stress and HMGB1/TLR4/NF-κB pathway.

Zhang X, Su C, Zhao S, Li J, Yu F Bioengineered. 2022; 13(2):2951-2970.

PMID: 35148668 PMC: 8973693. DOI: 10.1080/21655979.2021.2024686.

A Thrombomodulin Promoter Gene Polymorphism, rs2239562, Influences Both Susceptibility to and Outcome of Sepsis.

Watanabe E, Takasu O, Teratake Y, Sakamoto T, Ikeda T, Kotani J Front Med (Lausanne). 2022; 8:762198.

PMID: 35083232 PMC: 8785550. DOI: 10.3389/fmed.2021.762198.

Emerging therapeutic targets for sepsis.

Tindal E, Armstead B, Monaghan S, Heffernan D, Ayala A Expert Opin Ther Targets. 2021; 25(3):175-189.

PMID: 33641552 PMC: 8122062. DOI: 10.1080/14728222.2021.1897107.

References

Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y . Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg. 2012; 72(5):1150-7. DOI: 10.1097/TA.0b013e3182516ab5. View

Kudo D, Toyama M, Aoyagi T, Akahori Y, Yamamoto H, Ishii K . Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome. Clin Exp Immunol. 2013; 173(2):276-87. PMC: 3722928. DOI: 10.1111/cei.12106. View

Miyoshi S, Ito R, Katayama H, Dote K, Aibiki M, Hamada H . Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. Drug Des Devel Ther. 2014; 8:1211-9. PMC: 4159222. DOI: 10.2147/DDDT.S68030. View

Wada H, Aota T, Matsumoto T, Suzuki K, Imai H, Katayama N . Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers. J Thromb Haemost. 2015; 13(4):684-5. DOI: 10.1111/jth.12856. View

Abraham E . Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol. 2000; 22(4):401-4. DOI: 10.1165/ajrcmb.22.4.f184. View

Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T . Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015; 13(4):508-19. DOI: 10.1111/jth.12841. View

Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K . Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost. 1995; 74(5):1265-70. View

Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K . A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006; 34(3):625-31. DOI: 10.1097/01.ccm.0000202209.42491.38. View

Grommes J, Soehnlein O . Contribution of neutrophils to acute lung injury. Mol Med. 2010; 17(3-4):293-307. PMC: 3060975. DOI: 10.2119/molmed.2010.00138. View

10.

Panka B, de Grooth H, Spoelstra-de Man A, Looney M, Tuinman P . Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and Meta-Analysis of Clinical Studies. Shock. 2016; 47(1):13-21. PMC: 5175412. DOI: 10.1097/SHK.0000000000000745. View

11.

Bellani G, Laffey J, Pham T, Fan E, Brochard L, Esteban A . Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016; 315(8):788-800. DOI: 10.1001/jama.2016.0291. View

12.

Glas G, van der Sluijs K, Schultz M, Hofstra J, van der Poll T, Levi M . Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemost. 2012; 11(1):17-25. DOI: 10.1111/jth.12047. View

13.

Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D . 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250-6. DOI: 10.1097/01.CCM.0000050454.01978.3B. View

14.

Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T . Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med. 2013; 39(4):644-52. PMC: 3607733. DOI: 10.1007/s00134-013-2822-2. View

15.

Zampieri F, Mazza B . Mechanical Ventilation in Sepsis: A Reappraisal. Shock. 2016; 47(1S Suppl 1):41-46. DOI: 10.1097/SHK.0000000000000702. View

16.

Ware L, Matthay M, Parsons P, Thompson B, Januzzi J, Eisner M . Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2007; 35(8):1821-8. PMC: 2764536. DOI: 10.1097/01.CCM.0000221922.08878.49. View

17.

Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y . Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016; 115(6):1157-66. DOI: 10.1160/TH15-12-0987. View

18.

Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T . In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock. 2009; 33(3):282-8. DOI: 10.1097/SHK.0b013e3181b0ef7b. View

19.

Knaus W, Draper E, Wagner D, Zimmerman J . APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818-29. View

20.

Tagami T, Matsui H, Fushimi K, Yasunaga H . Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation. Front Med (Lausanne). 2015; 2:7. PMC: 4341430. DOI: 10.3389/fmed.2015.00007. View